Vendor Intelligence Report: Lejian Biotech Peptide

Published 3 Jul 2026. 27-page investigative report on who is behind Lejian Biotech Peptide: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 6 Finnrick lab tests, Lejian Biotech Peptide has 6 pass / 0 fail, for an overall pass rate of 100%. That headline is narrow rather than broad: every Finnrick-tested Lejian sample is Retatrutide. The record makes Lejian a more defensible gray-market option for Retatrutide than for untested catalog lines such as Tirzepatide or HGH, and the full report shows why stricter scoring and one weaker certificate-level result keep lot-level verification relevant.

The main buyer risk is operational, not a simple lab-quality verdict. The primary domain is in registrar clientHold and returning NXDOMAIN, with no replacement domain identified. Sales visibility now depends on GLP-1 Forum posts, Telegram, WhatsApp, and rotating Discord invites, while direct forum browsing was Cloudflare-blocked during the investigation.

Lejian presents as Hong Kong Lejian Biotechnology Co., Ltd., but the public accountability surface is still handle-led: Naomi, Helen, Tina, and other first-name contacts, without retrieved directors, registered-office details, or a verified commercial premises record. A public Janoshik search returned no Lejian results even though private COA links were posted, leaving Finnrick’s own testing as the strongest independent quality evidence.

The dossier also separates logistics strength from verification strength. Lejian advertised expanded overseas warehouses, acknowledged China-side regulatory tightening, and introduced an HGH line that was sold out pending restock; those facts matter differently from the clean Retatrutide record, especially amid border seizures, FDA GLP-1 warnings, scam impersonation, and crypto-payment recovery limits.

Inside the full report:

  • Retatrutide lab record, methodology-divergence analysis, and certificate exhibits
  • WHOIS, DNS, Wayback, and alternative-domain checks for the offline primary website
  • Corporate identity and personnel review for the Hong Kong legal name and named sales handles
  • GLP-1 Forum thread evidence covering inventory, warehouse claims, regulatory admission, and channel churn
  • Janoshik public-search exhibit and private-COA transparency analysis
  • Buyer-risk matrix covering HGH, import enforcement, impersonation, payments, and non-Retatrutide verification gaps

Risk assessment

  • Retatrutide fill-accuracy and methodology-sensitivity concern — medium: Retatrutide is Lejian’s strongest product with 6/6 Finnrick pass and an 84.9% rating, but stricter methodology views make lot-level fill verification relevant.
  • Non-Retatrutide peptide quality-verification gap — medium: Tirzepatide, Semaglutide, Cagrilintide, Tesamorelin, BPC-157/TB-500, NAD+, GLOW and related peptide lines have no Finnrick tests in the supplied record.
  • HGH product-line safety and legal-risk concern — high: H10/H12/H24/H36 HGH are marketed and restocked with no Finnrick testing; HGH is controlled in many jurisdictions and is not equivalent to the tested Retatrutide line.
  • Official-domain and communications-stability risk — high: lejianbiotech-peptide.com remains in clientHold with NXDOMAIN and no replacement domain; sales depend on Telegram, WhatsApp, Discord, and forum posts.
  • Impersonation and brand-verification risk — high: Lejian has posted 29+ scam warnings, channel links churn, crypto payment has no chargeback, and the vendor lacks a stable public anti-counterfeit framework.
  • Cross-border enforcement and supply-disruption risk — high: Lejian acknowledged China-side regulatory tightening, while CBP/FDA/TGA/Swissmedic activity targets GLP-1 and peptide shipments relevant to its warehouses and restocks.
  • Corporate-accountability risk — medium: The Lejian legal name is consistent, but registration number, directors, registered office, operating premises, and enforceable buyer-recource channels were not verified.